

**REMARKS**

The Examiner has required restriction to one of seven groups of claims. Applicant hereby elects, with traverse, to prosecute the claims of group II in this application (*i.e.*, claims 5, and 12-16 which are said to be drawn to a method of preparing a pharmaceutical composition for stimulatory T cells comprising expressing one or more antigens from diseased cells in antigen presenting cells and said composition comprising a cytokine and a bridge molecule, classified in class 435, subclass 455 and class 424, subclass 277.1). In order to expedite prosecution and advance the case towards issuance, Applicant has cancelled non-elected claims 1-4, 6-11, and 17-22, without prejudice.

The Examiner has also required Applicant to elect specific methods and compositions employing a specific species of antigen and bridge molecule. In order to expedite prosecution and advance the case towards issuance, Applicant hereby elects the methods and compositions wherein the bridge molecule is the CD 28:gp 55 bispecific antibody and the antigen is the CD 28 antigen.

**CONCLUSION**

Accordingly, the application is now in condition for allowance and a notice to that effect is respectfully requested. Enclosed is a check in the amount of \$680.00 which includes the fee for a four-month extension. If the enclosed fee is incorrect, please charge Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,

**LYON & LYON LLP**

Dated: 29 August 2000

By: 

Charles S. Berkman  
Reg. No. 38,077

633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066  
(858) 552-8400